China Biopharma Expansion Attracts Global Capital as Innovation Accelerates

China’s biotechnology sector is entering a new phase of financial maturity as companies move beyond heavy reliance on licensing agreements and tap deeper pools of domestic and international capital. Strong equity market performance, regulatory reforms and expanding innovation pipelines are reshaping the funding

Mainland Investors Chase Hong Kong Drug Stocks as Licensing Deals Gather Pace

Mainland Chinese investors have stepped up buying of Hong Kong listed pharmaceutical and biotech stocks, riding a renewed wave of overseas licensing agreements that is reshaping how China’s drug developers access global markets. The shift highlights growing confidence in innovative drug makers at